Sermorelin with GHRP-2 and GHRP-6
Sermorelin with GHRP-2 and GHRP-6 (compounded triple blend)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Sermorelin GHRP triple, Sermorelin/GHRP-2/GHRP-6
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
An old compounded blend, usually 3 mg of each in a 9 mg vial. Three names on the label. But two of the three hit the same hunger switch. So the label says thirds and your body sees a two to one split.
What people take it for
- Better sleep.
- Eating more.
- Losing fat and holding muscle.
- Recovery.
What the trials actually showed
The three way mix has never been tested. One GHRP plus GHRH has been. A 24 hour drip of that pair beat GHRH alone in healthy older adults. Thirty days of the GHRP alone kept growth hormone more than 1.8 times higher at day 14 and day 30. Sermorelin was an approved medicine and was compared against growth hormone itself in children who did not make enough. GHRP-6 has a human study too, just not an effect study. Nine healthy men got it by drip. Half life about 2.5 hours. The math: mix 9 mg with 3 mL and every unit mark carries 10 micrograms of each. Draw 20 units and you get 200 micrograms of sermorelin and 400 micrograms hitting the hunger switch, because both GHRPs add up there.
What people report
Reports, not trial results
The good
- Deep sleep in the first weeks.
The bad
- Hard hunger soon after the shot. Two of the three ingredients cause it.
- Flushing and a warm face.
- Water retention and tingling hands at bigger draws.
- Weight gain people struggle to separate from the eating.
- Lots of people drop this for a sermorelin and ipamorelin blend, and the hunger is why.
Where these come from: Clinic write-ups, men's health forums and peptide forums. The appetite effect is backed by a controlled human study of one of the ingredients.
My bottom line
Two hunger peptides in one vial is a choice, and the seller made it for you. If you are cutting, this is the wrong blend.
An opinion, not a finding. I am a coach, not a doctor.
Overview
A long-standing compounded triple, commonly 3 mg of each in a 9 mg vial or 2 mg of each in a 6 mg vial. Two of the three components are agonists at the same ghrelin receptor, so this is two mechanisms with one delivered twice, and the second delivery is the component with the strongest appetite effect in the family.
This blend predates most of the market and it is still dispensed. The rationale offered is that GHRP-2 and GHRP-6 have slightly different profiles and that using both covers more ground. Pharmacologically they are both agonists at the growth hormone secretagogue receptor, the ghrelin receptor, so the vial contains one receptor target hit by two drugs and one separate target hit by the third.
What that means in the syringe is worth spelling out. On a 9 mg vial with 3 mg of each, reconstituted with 3 mL, you have 3 mg/mL of total powder and 1 mg/mL of each component. One unit on a 100 unit insulin syringe carries 10 micrograms of each. At a 20 unit draw you have taken 200 micrograms of sermorelin and 400 micrograms of combined ghrelin-receptor agonist, because the two GHRPs add at the same receptor. The label presents three equal components; the receptor sees a two to one split.
GHRP-6 is the hungriest agent in the group. GHRP-2 also increases food intake in healthy men, measurably, in a controlled study. Putting both in one vial means the appetite effect is the one thing this blend reliably delivers, and there is no way to reduce it without reducing the GHRH component you presumably wanted.
On evidence, the class combination has been tested: in healthy older adults a 24 hour infusion of a ghrelin-receptor agonist with GHRH drove growth hormone secretion more than GHRH alone, and more than the agonist alone. That study used one GHRP, by infusion, in a research setting. Sermorelin itself carries the regulatory history, having been an approved product with paediatric growth hormone deficiency data behind it, including a comparative study against growth hormone itself. GHRP-6 has published human pharmacokinetics in nine male volunteers with an elimination half-life of about 2.5 hours. None of that describes this vial.
Mechanism of action
Sermorelin is GHRH 1-29 and raises the amplitude of a growth hormone pulse at the GHRH receptor. GHRP-2 and GHRP-6 are both hexapeptide agonists at the growth hormone secretagogue receptor, triggering a pulse and opposing somatostatin tone, and both also drive appetite through the same receptor. All three outputs converge on pituitary growth hormone release and then hepatic IGF-1.
Human evidence
No trial of the triple. The class pairing of one GHRP with GHRH has been shown to beat either alone on growth hormone output, using infusions.
- The blend: no published study, no registered trial.
- GHRH plus one GHRP: raised growth hormone above either agent alone in healthy older adults over a 24 hour infusion.
- Two GHRPs together: never studied in people.
- GHRP-2: increases food intake in healthy men; 30 days of infusion sustains a raised growth hormone axis.
- GHRP-6: single-dose human pharmacokinetics only, with no efficacy trial.
- Sermorelin: approval-era evidence in children with growth hormone deficiency.
What this does not tell you: Every endpoint in this literature is a hormone concentration. No trial of any of these three has measured body composition, recovery or function in healthy adults over the durations people use them.
What it has been measured to do
Measured in people
Goals Sermorelin with GHRP-2 and GHRP-6 has been measured for in a human being, most people first. Counts come from the study lines on this page and deliberately undercount.
- Feeling less hungryno headcount stated · 1 study
- Growth hormone and IGF-1no headcount stated · 1 study
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with Sermorelin with GHRP-2 and GHRP-6, what they expect, and what goes wrong. The full account, including the negative reports, is below.
34 of the 36 indexed goals have no study of any kind behind Sermorelin with GHRP-2 and GHRP-6
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about Sermorelin with GHRP-2 and GHRP-6 and one of these did not come from a study cited here.
Reading the research record
The two-GHRP design is the thing to understand before buying this. Whatever difference exists between GHRP-2 and GHRP-6 in cortisol or prolactin effect, both are agonists at one receptor, so combining them mostly increases exposure at that receptor rather than adding a capability. The visible consequence is appetite, which both drive, and which is the single most consistent report on this blend.
The second point is that a prescription does not mean a trial. Compounded preparations are not FDA approved and are not reviewed for safety or efficacy. The only component here with a regulatory history had it in children with a diagnosed deficiency, which is not the population buying a bedtime vial.
The evidence, charted
Fig. 1a · evidence scale
9people, across 1 human study cited here
- 2013 · European Journal of Pharmaceutical Sciences9100%
The whole total is one study of 9. Counts are the enrollment each human citation on this page states, which includes observational cohorts where nobody was given the compound. 3 further human citations state no participant count and are not counted here. Studies still recruiting are excluded, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 4 citations here are human work.
- Human · given to people4100%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 1993 to 2013, counted from the citation list on this page. The newest citation on file is from 2013, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- Not on file
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined for the blend. All three components clear quickly, and the published figure for the growth hormone releasing peptide component is in the overview above.
No amino acid sequence is on file for Sermorelin with GHRP-2 and GHRP-6, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
33.3%of a 9 mg Sermorelin with GHRP-2 and GHRP-6 vial is Sermorelin
- Sermorelin3 mg33.3%
- GHRP-23 mg33.3%
- GHRP-63 mg33.3%
Label mass from a standard vial, not a dose, and not an assay. The ratio is fixed by the seller, so a draw that hits the amount you want of one component sets the amount of every other component with it. No study has tested this combination in any species.
Key studies & citations
- Human2004
Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women
In healthy older adults, a 24 hour infusion of GHRP-2 combined with GHRH drove growth hormone secretion more than GHRH alone and more than GHRP-2 alone, and 30 days of continuous GHRP-2 sustained pulsatile growth hormone more than 1.8-fold at days 14 and 30 with IGF-1 on a plateau. One GHRP plus GHRH, by infusion, in a research setting. Nothing here supports adding a second agent at the same receptor.
Journal of Clinical Endocrinology and Metabolism - Human2005
Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men
GHRP-2 increased food intake in healthy men in the way ghrelin does. Both ghrelin-receptor components of this blend drive appetite, and their effects at that receptor add.
Journal of Clinical Endocrinology and Metabolism - Human2013
Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers
Nine healthy men, single intravenous boluses of 100, 200 and 400 micrograms per kilogram. Distribution half-life 7.6 plus or minus 1.9 minutes, elimination half-life 2.5 plus or minus 1.1 hours, with atypical concentration spikes during elimination in four of nine subjects.
European Journal of Pharmaceutical Sciences - Human1993
A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency
GHRH 1-29, the molecule sold as sermorelin, compared against growth hormone itself for stimulating growth in children with growth hormone deficiency. The kind of evidence behind sermorelin's former approval, in a paediatric deficiency population.
Acta Paediatrica Supplement
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Intense hunger shortly after injecting, the dominant report.
- Deep sleep in the first weeks.
- Flushing and warmth in the face.
- Water retention and tingling hands at larger draws.
- Weight gain that people find hard to separate from the appetite effect.
- People dropping the GHRP-6 component and moving to a sermorelin plus ipamorelin blend for that reason.
Sources: Clinic write-ups, men's health forums and peptide forums. Uncontrolled self-reports, except the appetite effect, which is supported by controlled human work on GHRP-2.
Frequently asked questions
Why are there two GHRPs in this?
Marketing reasons more than pharmacological ones. Both are agonists at the same growth hormone secretagogue receptor, so the vial gives you two mechanisms with one of them delivered twice.
What does a draw actually deliver?
On a 9 mg vial with 3 mg of each reconstituted with 3 mL, one unit carries 10 micrograms of each. A 20 unit draw is 200 micrograms of sermorelin and 400 micrograms of combined ghrelin-receptor agonist, because the two GHRPs add at the same receptor.
Why am I so hungry on this?
Both GHRPs drive appetite through the ghrelin receptor, and the effect of GHRP-2 on food intake has been measured in a controlled study in healthy men. With two of them in the vial, that is the effect you should expect.
Has the three-way combination been tested?
No. The combination evidence in this class used one GHRP with GHRH, by infusion, in healthy older adults.
Is a compounded blend better vetted than a research vial?
The supply chain is better. The evidence is the same. Compounded preparations are not FDA approved and are not reviewed for safety or efficacy.